

TRAF4 (D1N3A) Rabbit mAb



Orders: 877-616-CELL (2355)

orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com

cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: W	Reactivity: H M	Sensitivity: Endogenous	MW (kDa): 50	Source/Isotype: Rabbit IgG	UniProt ID: #Q9BUZ4	Entrez-Gene Id: 9618
Product Usage Information		Application Western Blotting			Dilution 1:1000	
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.				
Specificity/Sensitivity		TRAF4 (D1N3A) Rabbit mAb recognizes endogenous levels of total TRAF4 protein. An unknown background band is detected in some cell lines at 80kDa.				
Source / Purification		Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Arg124 of human TRAF4 protein.				
Background		surface receptors and promoting cellular resurtant TRAF domain", which terminal Zinc/RING fir their interactions with (TRAF1-6) act as adapting regulation of cell surva TRAF4, also referred tweak binding to TNFR neurotrophin receptometastatic breast care various cancers include suppressor p53 in resurctical shown to play a critical promoting cancers.	l recruit additional p sponses (1-3). Meml mediates interaction nger motifs. The firs the cytoplasmic do tor proteins for a wi ival, proliferation, do as CART1 and MLI family members (5 r p75-NGFR, lympho cinoma, TRAF4 has le ding breast, lung an ponse to DNA dama al role in TGF-β sign	are a family of multifunce or oteins to form multipropers of the TRAF family sons with associated profest TRAFs identified, TRAF or ange of cell surface ifferentiation, and stres N62, is a divergent mem (-7). Interactions have be otoxin-β receptor, and Goeen shown to contributed colon (11-13). Expressage, and can promote a laling, where it has been abilization driving breas	otein signaling comshare a common cateins; many also co 1 and TRAF2, were (TNFRII) (4). The six receptors and parts responses. aber of the TRAF faren observed between to tumor growth ion of Traf4 is indupoptosis (14).TRAF4 found to antagonic	nplexes capable of proxy-terminal nation aminofound by virtue of known TRAFs icipate in the mily with relatively een TRAF4 and the iginally identified in and invasion in ced by the tumor thas also been ze the E3 ligase
Background References		1. Arch, R.H. et al. (1998) <i>Genes Dev</i> 12, 2821-30. 2. Chung, J.Y. et al. (2002) <i>J Cell Sci</i> 115, 679-88. 3. Bradley, J.R. and Pober, J.S. (2001) <i>Oncogene</i> 20, 6482-91. 4. Rothe, M. et al. (1994) <i>Cell</i> 78, 681-92. 5. Kawamata, S. et al. (1998) <i>J Biol Chem</i> 273, 5808-14. 6. Régnier, C.H. et al. (1995) <i>J Biol Chem</i> 270, 25715-21. 7. Bièche, I. et al. (1996) <i>Cancer Res</i> 56, 3886-90. 8. Yang, K. et al. (2015) <i>Int J Clin Exp Pathol</i> 8, 1419-26. 9. Camilleri-Broët, S. et al. (2007) <i>Oncogene</i> 26, 142-7. 10. Li, W. et al. (2013) <i>Cancer Res</i> 73, 6938-50. 11. Ye, X. et al. (1999) <i>J Biol Chem</i> 274, 30202-8. 12. Esparza, E.M. and Arch, R.H. (2004) <i>Cell Mol Life Sci</i> 61, 3087-92. 13. Krajewska, M. et al. (1998) <i>Am J Pathol</i> 152, 1549-61. 14. Sax, J.K. and El-Deiry, W.S. (2003) <i>J Biol Chem</i> 278, 36435-44. 15. Zhang, L. et al. (2013) <i>Mol Cell</i> 51, 559-72.				

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4° C with gentle shaking, overnight.

Applications Key W: Western Blotting

Cross-Reactivity Key H: Human M: Mouse

Trademarks and Patents Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

force or effect.

All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for

more information.

Limited UsesExcept as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.